Neurovation Labs

Neurovation Labs is a biotechnology company pioneering the development of objective diagnostics and targeted treatments for Post-Traumatic Stress Disorder (PTSD). The company's core innovation involves identifying the upregulation of GluA1-containing AMPA receptors as a physiological biomarker for PTSD. Their pipeline features a proprietary PET imaging tracer designed to provide a definitive biological diagnosis, alongside a companion small molecule therapeutic. By moving beyond subjective symptom-based assessments, Neurovation Labs aims to provide personalized care for patients suffering from trauma-induced brain disorders. The company has received significant support from the U.S. Department of Defense and Air Force to advance its neuroscience-based solutions. Their approach represents a shift toward precision medicine in the field of psychiatry.